Table 4.
Summary of PASI75, 90, and 100 responses evaluating biologic agents in Phase III clinical trials for IL-23, IL-23/12, IL-17, and TNF-α inhibitors.
| Biologic | Dose | PASI 75 | PASI 90 | PAS 100 | |||
|---|---|---|---|---|---|---|---|
| Tildrakizumab (103) | 100 mg | 64% at 12 wks | 80% at 28 wks | 35% at 12 wks | 52% at 28 wks | 14% at 12 wks | 24% at 28 wks |
| 200 mg | 62% at 12 wks | 82% at 28 wks | 35% at 12 wks | 59% at 28 wks | 14% at 12 wks | 32% at 28 wks | |
| Tildrakizumab (103) | 100 mg | 61% at 12 wks | 73% at 28 wks | 39% at 12 wks | 56% at 28 wks | 12% at 12 wks | 23% at 28 wks |
| 200 mg | 66% at 12 wks | 73% at 28 wks | 37% at 12 wks | 58% at 28 wks | 12% at 12 wks | 27% at 28 wks | |
| Guselkumab (72) | 100 mg | 91.2% at 16 wks | 73.3% at 16 wks | 37.4% at 16 wks | |||
| Guselkumab (74) | 100 mg | 86.3% at 16 wks | 70% at 16 wks | 34.1% at 16 wks | |||
| Risanzikumab (79) | 150 mg | 86.8% at 12 wks | 75.3% at 16 wks | 35.9% at 16 wks | |||
| Risanzikumab (79) | 150 mg | 88.8% at 12 wks | 74.8% at 16 wks | 50.7% at 16 wks | |||
| Mirikizumab (82) | 100 mg | 78% at 16 wks | 59% at 16 wks | 31% at 16 wks | |||
| Mirikizumab (82) | 300 mg | 75% at 16 wks | 67% at 16 wks | 31% at 16 wks | |||
| Ustekinumab (51) | 90 mg | 66.4% at 12 wks | 78.6% at 28 wks | 36.7% at 12 wks | 55.6% at 28 wks | 10.9% at 12 wks | 29.2% at 28 wks |
| Ustekinumab (52) | 90 mg | 75.7% at 12 wks | 78.5% at 28 wks | 50.9% at 12 wks | 54.3% at 28 wks | 18.2% at 12 wks | 29.5% at 28 wks |
| Secukinumab (135) | 150 mg | 67% at 12 wks | 41.9% at 12 wks | 14.4% at 12 wks | |||
| Secukinumab (135) | 300 mg | 77.1% at 12 wks | 54.2% at 12 wks | 24.1% at 12 wks | |||
| Ixekizumab (123) | 160 mg q2w | 89.1% at 12 wks | 70.9% at 12 wks | 35.3% at 12 wks | |||
| Ixekizumab (123) | 160 mg q4w | 82.6% at 12 wks | 64.6% at 12 wks | 33.6% at 12 wks | |||
| Brodalumab (136) | 140 mg | 60.3% at 12 wks | 42.5% at 12 wks | 23.3% at 12 wks | |||
| Brodalumab (136) | 210 mg | 83.3% at 12 wks | 70.3% at 12 wks | 41.9% at 12 wks | |||
| Bimekizumab (137) | 160 mg | 81.4% at 12 wks | 67.4% at 12 wks | 27.9% at 12 wks | |||
| Bimekizumab (137) | 320 mg | 93.1% at 12 wks | 79.1% at 12 wks | 55.8% at 12 wks | |||
| Etanercept (135) | 50 mg | 44% at 12 wks | 20.7% at 12 wks | 4.3% at 12 wks | |||
| Infliximab (138) | 5 mg/kg | 75.5% at 10 wks | 45.2% at 10 wks | ||||
| Adalimumab (139) | 40 mg | 37% at 12 wks | 14% at 12 wks | ||||
| Certolizumab pegol (140) | 200 mg | 61.3% at 12 wks | 31.2% at 12 wks | ||||
| Golimumab (141) | 2 mg/kg | 59.2% at 14 wks | 39.3% at 14 wks | 16.8% at 14 wks |